शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
BSEGUJARAT TERCE LABORATORIES LTD· Pharmaceuticals & BiotechnologyHighNeutral
Announced Fri, 7 Aug, 2026 · 16:51 IST

Q1 FY27 results: Revenue declines 17% YoY, loss widens

Revenue DeclinePat NegativeResults View source PDFExplain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-13.8%Reaction day
₹43.00
prior close
₹38.10
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-13.8% vs market
Pharmaceuticals peers, median of 165sector-0.1%-13.8% vs sector

On the reaction day the stock moved 13.8 pts less than Nifty Microcap 250 and 13.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+3.4
10m
+3.4
15m
-0.3
30m
-0.3
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-13.8-0.1-13.8-0.1-13.8
Next day
-13.7-0.2-13.5+0.0-13.8
2d
-8.6+0.1-8.8-0.0-8.6
3d
-14.0+0.3-14.3+0.3-14.3
4d
-10.0+0.4-10.4-0.5-9.5
5d
-7.6+0.5-8.1-1.1-6.4
1w
-16.3+0.3-16.5-1.8-14.4
15d
-10.3+1.9-12.2+0.2-10.6
1m
-10.4+2.2-12.6+1.7-12.1
2m
-3.5-1.2-2.3-1.8-1.7
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Gujarat Terce Laboratories reported Q1 FY27 revenue of 900.24 lakh, down about 17% from 1085.36 lakh in Q1 FY26. Total expenses of 963.35 lakh exceeded total revenue, leading to a loss before tax of 14.88 lakh versus 7.10 lakh loss last year. Net loss widened to 17.81 lakh from 4.35 lakh, with EPS at minus 0.23 versus minus 0.06. The statutory auditor issued an unmodified limited review report.

Likely market impact

Second straight quarter of losses with shrinking revenue and expenses exceeding income signals operational pressure. Investors should watch for margin recovery.